Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.74 USD
+0.01 (0.58%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $1.74 0.00 (0.00%) 4:46 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
ESPR 1.74 +0.01(0.58%)
Will ESPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
Other News for ESPR
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
Commit To Purchase Esperion Therapeutics At $1.50, Earn 36% Annualized Using Options
Market Outperform: Enhanced Insurance Coverage and FDA Approvals Propel Esperion’s Growth Potential
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL? (bempedoic acid) and NEXLIZET? (bempedoic acid and ezetimibe)
Esperion secures additional commercial, Medicare formulary coverage for NEXLETOL